Dual neutralization of IL-17A and IL-17F with bimekizumab improves quality of life in patients withmoderate-to-severe plaque psoriasis: results from a Phase 2b study and correlation with clinical response. J of Skin. 2018;2:S92. doi:10.25251/skin.2.supp.93